ES2033212A6 - Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados. - Google Patents

Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.

Info

Publication number
ES2033212A6
ES2033212A6 ES08904164A ES8904164A ES2033212A6 ES 2033212 A6 ES2033212 A6 ES 2033212A6 ES 08904164 A ES08904164 A ES 08904164A ES 8904164 A ES8904164 A ES 8904164A ES 2033212 A6 ES2033212 A6 ES 2033212A6
Authority
ES
Spain
Prior art keywords
pct
date
production
ancrod
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08904164A
Other languages
English (en)
Inventor
Alfred Bach
Karl-Hermann Strube
Wolfgang Koerwer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of ES2033212A6 publication Critical patent/ES2033212A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procedimiento para la obtención de péptidos puramente glicosilados, parcialmente glicosilados o no glicosilados con la secuencia de aminoácidos: 1 viggdecnin ehrflvavye gtx 1 wtficgg vlihpewvit aehcarrrmn 51 lvfgmhrkse kfddeqeryp kkryfircx 2k trtswdedim lirlnkpvx 3n 101 sehiaplslp snppivgsdc rvmgwgsinr rihvlsdepr caninlhx 4ft 151 mchglfrkmp kkgrvlcagd lrgrrdscns dsggplicne elhgivargp 201 npcaqpnkpa lytsvydyrd wvnnviagx 5a tcsp Comprende aislar el mRNA de un organismo adecuado; traducirlo en cDNA de doble hebras; aplicar este cDNA en un vector de clonación; y aplicar posteriormente una biblioteca cDNA, para expresar así secuencias de DNA en dicho organismo huesped que codifiquen las secuencias de péptido anteriormente indicados. Los péptidos son adecuados para la lucha contra enfermedades.
ES08904164A 1988-12-10 1989-12-07 Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados. Expired - Lifetime ES2033212A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3841736A DE3841736A1 (de) 1988-12-10 1988-12-10 Ancrod-proteine, ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
ES2033212A6 true ES2033212A6 (es) 1994-05-01

Family

ID=6368940

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08904164A Expired - Lifetime ES2033212A6 (es) 1988-12-10 1989-12-07 Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.

Country Status (11)

Country Link
US (1) US6015685A (es)
EP (1) EP0447468B1 (es)
JP (1) JP2783296B2 (es)
AT (1) ATE123056T1 (es)
AU (1) AU637589B2 (es)
BR (1) BR1100940A (es)
CA (1) CA2004764C (es)
DE (2) DE3841736A1 (es)
ES (1) ES2033212A6 (es)
HU (1) HU211658A9 (es)
WO (1) WO1990006362A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759541A (en) * 1990-07-26 1998-06-02 Basf Aktiengesellschaft Recombinant fibrinogenases, the preparation and use thereof
DE4023699A1 (de) * 1990-07-26 1992-01-30 Basf Ag Neue proteine, ihre herstellung und verwendung
DE19729544A1 (de) 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN108559740B (zh) * 2018-05-12 2021-05-18 吉林天衡康泰生物技术有限公司 重组安克洛酶及工业规模制备方法和治疗急性脑梗的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879369A (en) * 1972-05-12 1975-04-22 Abbott Lab Anti-coagulant isolation from malayan pit viper using affinity chromatography
DE2615844A1 (de) * 1976-04-10 1977-10-20 Knoll Ag Fibrinogen spaltendes enzymsystem
ZA889415B (en) * 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
CA2015127A1 (en) * 1989-04-26 1990-10-26 John G. Gray, Jr. Novel dna sequences which encode ancrod-like polypeptides and compositions comprising the expression products thereof
DE4023699A1 (de) * 1990-07-26 1992-01-30 Basf Ag Neue proteine, ihre herstellung und verwendung

Also Published As

Publication number Publication date
BR1100940A (pt) 2000-08-01
JP2783296B2 (ja) 1998-08-06
CA2004764A1 (en) 1990-06-10
EP0447468A1 (de) 1991-09-25
DE3841736A1 (de) 1990-07-05
CA2004764C (en) 1999-07-06
WO1990006362A1 (de) 1990-06-14
HU211658A9 (en) 1995-12-28
AU4664489A (en) 1990-06-26
EP0447468B1 (de) 1995-05-24
DE58909261D1 (de) 1995-06-29
JPH04502252A (ja) 1992-04-23
ATE123056T1 (de) 1995-06-15
AU637589B2 (en) 1993-06-03
US6015685A (en) 2000-01-18

Similar Documents

Publication Publication Date Title
EP0158286A3 (en) A novel human physiologically active polypeptide
DE69533556D1 (de) N-terminal modifizierte Polypeptide, und Herstellungsprozess
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
HU9200548D0 (en) Improved activity process of recombined proteins
WO2000034474A3 (en) Growth factor homolog zvegf3
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
TW275066B (es)
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
AU637589B2 (en) Ancrod proteins, their production and use
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
CA2056467A1 (en) Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
EP0723016A3 (en) Leukocyte activation factor
WO1992001794A3 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung
DE68916559D1 (de) Polypeptide und dafür kodierende DNA.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19930920